Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: Safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine

AIDS

Volumn 19, Issue 12, 2005, Pages 1321-1323

  Dorrell, Lucy ^a   Yang, Hongbing ^a   Iversen, Astrid K N ^a   Conlon, Christopher ^b   Suttill, Annie ^c   Lancaster, Mary ^c   Dong, Tao ^a   Cebere, Inese ^a   Edwards, Anne ^c   Rowland Jones, Sarah ^a   Hanke, Tomáš ^a   McMichael, Andrew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MALE; PRIORITY JOURNAL;

EID: 24044438267     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000180104.65640.16     Document Type: Article

References (13)

1. Hanke T, McMichael A. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat Med 2000; 6:951-955.
2. Jin X, Ramanathan M Jr, Barsoum S, Deschenes G, Ba L, Binley J, et al. Safety and immunogenicity of ALVAC vCP1452and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy. J Virol 2002; 76:2206-2216.
3. Hanke T, Samuel R, Blanchard TJ, Neumann VC, Allen TM, Boyson JE, et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multi-epitope DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol 1999; 73:7524-7532.
4. McConkey S, Reece W, Moorthy V, Webster D, Dunachie S, Butcher G, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003; 9:729-735.
5. Barouch D, Santra S, Schmitz J. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000; 290:486-492.
6. MacGregor R, Boyer J, Ugen K, Lacy K, Gluckman S, Bagarazzi M, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998; 178:92-100.
7. Calarota S, Bratt G, Nordlund S, Hinkula J, Leandersson A-C, Sandstrom E, et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998; 351:1320-1325.
8. Lange C, Lederman M, Medvik K, Asaad R, Wild M, Kalayjian R, et al. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS 2003; 17:2015-2023.
9. Oxenius A, Price DA, Easterbrook PJ, O'Callaghan CA, Kelleher AD, Whelan JA, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci USA 2000; 97:3382-3387.
10. Rosenberg E, Altfeld M, Poon S. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407: 523-526.
11. Mwau M, Cebere I, Sutton J, Chikoti P, Winstone N, Wee EG-T, et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 2004; 85:911-919.
12. Calarota S, Leandersson A, Bratt G, Hinkula J, Klinman D, Weinhold K, et al. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. J Immunol 1999; 163:2330-2338.
13. Radaelli A, Nacsa J, Tsai W-P, Edghill-Smith Y, Zanotto C, Elli V, et al. Prior DNA immunization enhances immune response to dominant and subdominant viral epitopes induced by a fowlpox-based SIVmac vaccine in long-term slow-progressor macaques infected with SIVmac251. Virology 2003; 312: 181-195.